Hybridan

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Your Partner for Growth

Your Partner for Growth, Hybridan

Equity Bottom-Up

<ul><li>Friday Takeaway—delving a little deeper into UK small caps Friday Takeaway from UK Small Caps This will delve a little deeper on individual companies and focus on non-house stocks under £200m market capitalisation to raise awareness 14th March 2025 Alphabetically arranged Share prices and market capitalisations taken from Alpha Terminal from the current price on the day of publication.</li><li>Top three shareholders are taken from the websites of the companies that we are writing about, unless there is a more up to date TR-1 notification RNS announcement.</li><li> Disruptive changes could generate opportunities for these two companies ABDX Flowing Downhill NXQ Follow the Money Abingdon Health 6.75p £12.32m (ABDX) Financial Calendar: Year End June, Report October, Interims December, Report April Three Main Shareholders: Octopus Investments Limited 10.1%, Cannacord Genuity Group Inc 9.7% Mercia 9.3% Key Investment Points: Fund Raise, Acquisition, US office Opened, Growth should follow Interims to December 2024 are due to be reported by this lateral flow test contract research (CRO) and contract development and manufacturing organisation (CDMO).</li></ul>

Friday Takeaway—delving a little deeper into UK small caps Friday Takeaway from UK Small Caps This will delve a little deeper on individual companies and focus on non-house stocks under £200m market capitalisation to raise awareness 14th March 2025 Alphabetically arranged Share prices and market capitalisations taken from Alpha Terminal from the current price on the day of publication.Top three shareholders are taken from the websites of the companies that we are writing about, unless there is a more up to date TR-1 notification RNS announcement. Disruptive changes could generate opportunities for these two companies ABDX Flowing Downhill NXQ Follow the Money Abingdon Health 6.75p £12.32m (ABDX) Financial Calendar: Year End June, Report October, Interims December, Report April Three Main Shareholders: Octopus Investments Limited 10.1%, Cannacord Genuity Group Inc 9.7% Mercia 9.3% Key Investment Points: Fund Raise, Acquisition, US office Opened, Growth should follow Interims to December 2024 are due to be reported by this lateral flow test contract research (CRO) and contract development and manufacturing organisation (CDMO).

Nexteq PLC - Friday Take Away: 14 March 2025